BUDDY: Bidirectional, Upbeat Communication and Differentiated, Distanced Care for Young People

Sponsor
Desmond Tutu HIV Foundation (Other)
Overall Status
Completed
CT.gov ID
NCT04781400
Collaborator
ViiV Healthcare (Industry), Karolinska Institutet (Other), University of North Carolina, Chapel Hill (Other), University of KwaZulu (Other)
536
1
2
15.1
35.5

Study Details

Study Description

Brief Summary

Sub Saharan Africa is home to only 12% of the population, but accounts for approximately 70% of the global burden of HIV infection and 84% of infections among young people aged 10-24 years. South Africa, which currently has the largest SARS-CoV-2 pandemic in SSA, also has the largest HIV epidemic globally. Access and service delivery barriers to engaging in HIV care have contributed to estimates that only 49% of adolescents (aged 10-19 years) entering care from 2005-2016 have initiated antiretroviral therapy (ART). In response to the SARS-CoV-2 pandemic the South African government has implemented national lock-down orders that we predict will further inhibit treatment engagement among young people. Research is needed to identify best practices for safely retaining young people living with HIV (YPLWH) in care during COVID-19.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Mobile phone support
  • Behavioral: Remote service delivery model
N/A

Detailed Description

The primary objectives of this study are to examine the feasibility, acceptability, and preliminary efficacy of a remote service delivery model for young people living with HIV aged 13-24 years that will include a monthly service needs assessment and optional delivery of HIV treatment services. YPLWH will also be randomized to receive (or not receive) mobile check-ins from study staff and access to two-way messaging capabilities to obtain continuous support for adherence to ART and COVID-19 prevention guidelines.

Investigators will also assess the impact of the COVID-19 lock-down orders on multi-level factors (individual, socio-behavioral, structural) over time among young people aged 13-24 years living with HIV (same cohort as above) and without HIV. Particular focus will be given to experience and perpetration of gender based violence. In addition, investigators will assess the impact of multi-level factors on compliance with COVID-19 prevention guidelines, health service utilization, and engagement in HIV care (YPLWH only). Findings will be examined overall and stratified by HIV status and gender.

Ultimately investigators hope to: (i) determine whether a remote service delivery model will help retain young people in HIV care and (ii) Inform the development of an intervention for young people in the study communities who may be experiencing GBV and associated outcomes in the wake of the pandemic.

Study Design

Study Type:
Interventional
Actual Enrollment :
536 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Health Services Research
Official Title:
Bidirectional, Upbeat Communication and Differentiated, Distanced Care for Young People
Actual Study Start Date :
Feb 8, 2021
Actual Primary Completion Date :
May 13, 2022
Actual Study Completion Date :
May 13, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Remote service delivery model PLUS mobile phone support

Remote service delivery plus mobile intervention via SMS will include weekly check-ins from study staff, calls from a trained counsellor on request, and access to a two-way messaging feature.

Behavioral: Mobile phone support
Mobile phone support (SMS)

Behavioral: Remote service delivery model
ART treatment delivery via a courier service

Active Comparator: Remote service delivery model

Remote service delivery model.

Behavioral: Remote service delivery model
ART treatment delivery via a courier service

Outcome Measures

Primary Outcome Measures

  1. Acceptability of a remote service delivery and mobile support intervention assessed by the number of participants opting in to receive courier delivery of ART. [6 months]

    Program evaluation of a remote service delivery including mobile support intervention and courier delivery of ART amongst young people living with HIV.

  2. Engagement in HIV care assessed by serial measurements of HIV Viral load. [6 months]

    Measurement of HIV viral load will be done at baseline, month three and month six to determine whether adherence to ART has been met (decrease or increase in HIV Viral load)

  3. Changes in Gender Based Violence (GBV) incidence as a result of COVID lock-down measures as assessed by self reported surveys. [6 months]

    Investigate changes in self-reported GBV experience or perpetration, and other individual, social-behavioral, and structural factors that have been impacted by COVID-19 lock down orders.

Secondary Outcome Measures

  1. Incidence of COVID-19 infection by assessing participant IgG antibody levels. [6 months]

    Retrospective COVID-19 antibody testing at baseline and month

  2. Qualitative themes assessed from in-depth individual interview data [6 months]

    Qualitative interviews will be used to inform intervention utility and the development of an intervention to reduce GBV

Eligibility Criteria

Criteria

Ages Eligible for Study:
13 Years to 24 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:

Young people living with HIV who meet all of the following criteria will be eligible for inclusion into this study:

  1. Speak isiXhosa and or English, residing in the Khayelitsha /Mitchell's Plain area

  2. 13-24 years (inclusive)

  3. Willing and able to provide informed telephonic or in person consent

  4. Initiated ART at one of two health facilities and are currently in HIV care (i.e. received ART and had a viral load measurement in the past six months)

  5. Regular access to a mobile phone with SMS or WhatsApp capacity (can include the phone of a parent/caregiver if the participant is <18 years or does not have their own phone)

Young people living without HIV from the same communities who meet all of the following criteria will be eligible for inclusion into this study:

  1. Speak isiXhosa and or English, residing in the Khayelitsha / Mitchell's Plain area

  2. 13-24 years (inclusive)

  3. Willing and able to provide informed telephonic or in person consent

  4. Has not previously tested positive for HIV and self-reports being HIV negative (i.e., not known to be living with HIV).

  5. Regular access to a mobile phone (can include the phone of a parent/caregiver if the participant is <18 years or does not have their own phone)

Exclusion Criteria:

Young people living with HIV who meet any of the following criteria will be excluded from this study:

  1. Not 13-24 years (inclusive)

  2. Unwilling or unable to provide informed telephonic or in person consent

  3. Not currently receiving ART care at a Desmond Tutu Health Foundation health facility

  4. No regular access to a mobile phone with SMS or WhatsApp capacity

  5. Planning to relocate in the next 6 months

Young people living without HIV from the same communities who meet any of the following criteria will be excluded this study:

  1. Not 13-24 years (inclusive)

  2. Unwilling or unable to provide informed telephonic or in person consent

  3. Previously tested positive for HIV or is known to be living with HIV

  4. No regular access to a mobile phone

  5. Planning to relocate in the next 6 months

Contacts and Locations

Locations

Site City State Country Postal Code
1 Gugulethu Community Health Centre Cape Town Western Cape South Africa 7806

Sponsors and Collaborators

  • Desmond Tutu HIV Foundation
  • ViiV Healthcare
  • Karolinska Institutet
  • University of North Carolina, Chapel Hill
  • University of KwaZulu

Investigators

  • Principal Investigator: Linda-Gail Bekker, Desmond Tutu HIV Foundation

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Desmond Tutu HIV Foundation
ClinicalTrials.gov Identifier:
NCT04781400
Other Study ID Numbers:
  • 448/2020
First Posted:
Mar 4, 2021
Last Update Posted:
Aug 17, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 17, 2022